Ultivue's Scientific Team Presents Compelling Tissue Marker Multiplexing Data at the American Association for Cancer Research (AACR) Annual Meeting 2018
CAMBRIDGE, Mass, April 16, 2018 – Ultivue has announced today the release of exciting new data illustrating the performance of its proprietary InSituPlex™ technology that powers the company’s reagent offering. Ultivue’s high- quality, kit-based products enable unsurpassed protein biomarker detection and analysis in tissue, with no compromise on level of multiplexing or sample staining and imaging throughput, and with no requirement of dedicated instrumentation. Dr. Michael Natan, Ultivue’s Chief Executive Officer, “We are very excited to demonstrate, through a compelling data set, that our products provide the performance and flexibility demanded in a wide range of use cases from clinical research and translational research to discovery applications.”
Ultivue’s scientific team is presenting 4 posters at the Emerging Proteomic Technologies for Cancer Research poster session on Wednesday 18 April, 2018 from 8:00 AM to 12.00 PM. Attendees at this important meeting (April 14-18, Chicago, IL), will gain insight into how an array of cancer types, including Non-Small Cell Lung Cancer (NSCLC), melanoma and breast carcinomas, can easily be interrogated for the presence of immuno-oncology markers using Ultivue’s ImmunoProfiler kits on a single slide, and with single staining, signal amplification, and imaging steps. The posters also illustrate benchmarked equivalent performance vs. conventional DAB and TSA-based immuno-histochemistry methods. However, compared to TSA-based approaches, Ultivue’s InSituPlex technology provides the important added benefits of (i) higher multiplexing level on single slide for whole slide imaging, (ii) dramatically improved usability, (iii) enhanced workflow integration, and (iv) preservation of sample integrity for downstream experiments.
“In addition to delivering excellent data quality, our assay panels seamlessly integrate with common immunohistochemistry workflows to deliver fast, high quality sample-to-image data. Up to 30 individual tissue sample slides are routinely stained in our labs, as a single batch, using an optimized, automated protocol. Within a work day, all 30 samples are stained and imaged as whole slides with a conventional multispectral scanner”, says Philippe Mourere, SVP Commercial Operations. “Such throughput provides significant gains of productivity to those labs requiring fast and detailed sample-to-data tumor profiling information”, adds Mourere.
Ultivue’s scientific personnel will be present at the company booth #3402 throughout the duration of the meeting conference to engage with the scientific community.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com
For Research Use Only. Not for use in diagnostic procedures.